Lamisil cream

国: アルメニア

言語: 英語

ソース: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

有効成分:

terbinafine (terbinafine hydrochloride)

から入手可能:

GSK Consumer Healthcare SARL

ATCコード:

D01AE15

INN（国際名）:

terbinafine (terbinafine hydrochloride)

投薬量:

10mg/g

医薬品形態:

cream

パッケージ内のユニット:

15g aluminium tube, 15g laminated tube

処方タイプ:

OTC

認証ステータス:

Registered

承認日:

2022-11-03

製品の特徴

Global Drug Regulatory Affairs
LAMISIL1% CREAM
Terbinafine
SUMMARY OF PRODUCT CHARACTERISTICS
Property of GSK Consumer Healthcare SARL
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of GSK Consumer Healthcare SARL
CONTENTS
1.
NAME OF THE MEDICINAL PRODUCT
...............................................................................
3
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
..................................................... 3
3.
PHARMACEUTICAL FORM
....................................................................................................
3
4.
CLINICAL PARTICULARS
......................................................................................................
3
4.1.
Therapeutic indications
..................................................................................................
3
4.2.
Posology and method of administration
.........................................................................
3
4.3.
Contra-indications
..........................................................................................................
4
4.4.
Special warnings and precautions for use
......................................................................
4
4.5.
Interactions with other medicinal products and other forms of
interaction ................... 5
4.6.
Pregnancy and lactation
.................................................................................................
5
4.7.
Effects on ability to drive and use machines
................................................................. 5
4.8.
Undesirable effects
.........................................................................................................
5
4.9.
Overdose
........................................................................................................................
6
5.
PHARMACOLOGICAL PROPERTIES
....................................................................................
6
5.1.
Pharmacodynamic properties
.........................................